2007 PREVIEW: Great expectations

Catherine Doherty, principal, Investit

OTC derivatives will continue to dominate the buy side's operational and technological priorities. Investment managers and outsourcers are developing long-term plans to support OTCs – firms are currently formalising OTC governance procedures. They are also prioritising OTC pricing and valuation data, collateral management and improved IT solutions to handle OTC complexity.

The MiFID requirement for best execution of OTCs will create a vigorous debate on

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: